8/7/2019 Mega Subscription new Ad English FN 3 Page
3/3
.DSIJ.i
RevIewSRecommenDatIonS
Sales 294.23 277.31 257.70 253.52 236.03OperatingProfit 34.67
40.56 40.08 35.99 28.23
Depreciation 4.68 4.64 4.67 4.37 4.37
NetProfit/Loss 20.98 25.62 23.78 21.12 16.49
EquityCapital 23.73 23.73 23.73 23.73 23.73
Last Five Quarters (`/C) S10 J10 mr10 D09 S09
Ticker:526612 H/L:`1,323/570 Percentage:5
BlueDaRtexpReSS
We had recommended Blue Dart Express to our investors inIssue No
22 dated August 2, 2010 when the scrip was tradingat ` 1,094. Our
recommendation was backed by factors
such as the increase in trade activities in the domestic aswell
as the international markets. This would have increasedthe
opportunities for the company. It delivered a goodperformance in
9MCY10 by posting a bottomline of` 70.38crore as against ` 39.58
crore in 9MCY09. Currently the scriphas witnessed a decline as
compared to our recommendedprice. At its current levels our
recommendation is that youshould hold the counter with a
perspective of two quarters ascompany may provide some financial
guidance.
Ticker:524715 H/L:`511/280FV:`1Equity:103.56Cr
SunphaRmaceutIcalS
This seems to be the right time to invest in SunPharmaceuticals
which is back on the growth path. Afterwinning full control over
Taro Pharma, it is now on its way
to get its US subsidiary Caraco back in action. Sun Pharmaearns
nearly half of its revenues from the domestic market. Ithas a share
of around 3.7 per cent in the domestic pharmamarket. The
consolidation of Taro is a high point for SunPharma during this
fiscal as it is an EPS-accretive acquisition.On the financial
front, for the 12 months ended September2010 the company has posted
an increase of 22 per cent inconsolidated revenues and a 27 per
cent rise in net earnings.Our recommendation is that investors
should buy the scripat its current levels with a target price of`
530.
Buy:`463 Target: ` 530 Rec. Price`1,094 CMP` 1,048
Sales 808.05 758.69 680.47 702.44 664.13OperatingProfit 337.33
310.84 248.94 318.36 264.56
Depreciation 12.38 17.82 20.19 15.40 16.62
NetProfit/Loss 345.72 322.63 256.04 318.04 203.06
EquityCapital 103.56 103.56 103.56 103.56 103.56
Last Five Quarters (`/C) S10 J10 mr10 D09 S09
FsnsIsJry30,20115
